高分化甲状腺肿瘤中分化型高级别甲状腺癌的患病率:系统综述与Meta分析
该系统综述与Meta分析评估了按当前WHO分类新定义的分化型高级别甲状腺癌(DHGTC)在分化良好的甲状腺癌(WDTC)中的患病率:临床未选择患者中为0.072(95%CI 0.045-0.113),滤泡性甲状腺癌(FTC)为0.146(95%CI 0.101-0.205)高于乳头状甲状腺癌(PTC)的0.059(95%CI 0.036-0.097),预后不良患者中高达0.287(95%CI 0.155-0.469)。
要点
- 临床未选择WDTC患者中DHGTC患病率为0.072(95%CI 0.045-0.113)。
- FTC患病率0.146(95%CI 0.101-0.205)高于PTC的0.059(95%CI 0.036-0.097)。
- 预后不良患者中DHGTC比例为0.287(95%CI 0.155-0.469),提示高级别特征与不良结局相关。
核心结论
- 按照当前WHO分类,部分WDTC将被重新分类为DHGTC;高级别特征在FTC、实性小梁型和 histological aggressive PTC亚型中比例较高,且在预后不良患者中富集,证实高级别特征对结局的负面影响。
研究设计与样本
- 系统综述与Meta分析,纳入报告WDTC中坏死和/或核分裂象数据的研究,以估计DHGTC患病率,并评估异质性和发表偏倚,遵循PRISMA指南,采用改良Newcastle-Ottawa量表进行质量评价,研究注册于PROSPERO(ID: CRD42022378716)。
主要发现
- 临床未选择患者中,WDTC中DHGTC患病率为0.072(95%CI 0.045-0.113)。
- FTC中DHGTC患病率为0.146(95%CI 0.101-0.205),高于PTC的0.059(95%CI 0.036-0.097)。
- 弥漫硬化型、滤泡型和经典型PTC的高级别特征率最低,分别为0.018(95%CI 0.004-0.084)、0.036(95%CI 0.010-0.124)和0.042(95%CI 0.027-0.066)。
- 实性小梁型和 histological aggressive PTC可被重新分类为DHGTC的比例较高,分别为0.154(95%CI 0.067-0.314)和0.168(95%CI 0.108-0.252)。
- 微小浸润型和广泛浸润型FTC中DHGTC比例相似,分别为0.136(95%CI 0.058-0.287)和0.152(95%CI 0.086-0.254);预后不良患者(死亡、转移、碘难治、生化复发)中DHGTC比例为0.287(95%CI 0.155-0.469)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The current edition of the World Health Organization (WHO) classification of endocrine tumors introduced grading for follicular cell-derived thyroid cancer. Tumors with necrosis and/or high mitotic count but not fulfilling the Turin criteria for poorly differentiated carcinoma will be reclassified as differentiated high-grade thyroid carcinoma (DHGTC). However, the impact of this reclassification has not been evaluated. In this study, we performed a systematic review and meta-analysis to estimate the prevalence of this new entry across thyroid tumor subtypes. Methods: In this systematic review and meta-analysis, studies reporting data on necrosis and/or mitoses in well-differentiated thyroid carcinoma (WDTC) were used to estimate the prevalence of DHGTC. Heterogeneity and potential publication bias were also evaluated. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed, and quality assessment was performed using a modification of the Newcastle-Ottawa scale. The study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO, ID: CRD42022378716). Results: In clinically unselected patients, the prevalence of DHGTC in WDTC was 0.072 [95% confidence interval, CI, = 0.045-0.113]. The proportion of high-grade tumors greatly varied across growth patterns and subtypes. Overall, the prevalence of DHGTC was higher in follicular thyroid carcinoma (FTC; 0.146 [CI = 0.101-0.205]) than in papillary thyroid carcinoma (PTC; 0.059 [CI = 0.036-0.097]). Diffuse sclerosing, follicular, and classic subtype PTC had the lowest rates of high-grade features (i.e., 0.018 [CI = 0.004-0.084]; 0.036 [CI = 0.010-0.124]; and 0.042 [CI = 0.027-0.066], respectively), while a greater proportion of solid trabecular and histologically aggressive PTC could be reclassified as DHGTC (i.e., 0.154 [CI = 0.067-0.314] and 0.168 [CI = 0.108-0.252], respectively). Similar proportions were obtained for minimally and widely invasive FTC (i.e., 0.136 [CI = 0.058-0.287] and 0.152 [CI = 0.086-0.254], respectively). Finally, in a cohort of patients with poor prognosis (i.e., fatal cases, metastatic and radioiodine resistant tumors, cases with biochemical recurrence), the proportion of DHGTC was 0.287 [CI = 0.155-0.469]. Conclusions: Following the current WHO indications, some tumors will be reclassified as DHGTC. The proportion of tumors with high-grade features is relevant in FTC, solid trabecular, and histologically aggressive PTC subtypes. A remarkable enrichment in DHGTC among patients with poor prognosis confirms the negative impact of high-grade features on outcome.
引用
- Poma AM, Macerola E, Ghossein RA, et al. Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis. Thyroid. 2024. PMID: 38115626. doi:10.1089/thy.2023.0350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。